BioSpace News Archive

Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced that it will report full year 2020 financial results on Tuesday, February 16, 2021. Baudax’s management team will host a conference call and webcast at 8:00 a.m. ET on Tuesday, February 16, 2021 to discuss the financial results and recent operational highlights.

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for TJ210/MOR210 to initiate a phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics

Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it will host a virtual R&D Day at 10:00 am - 2:00 pm ET / 7:00 - 11:00 am PT on Wednesday, February 24, 2021.

Soliton, Inc., a medical device company with a novel and proprietary aesthetic platform technology, announced Brad Hauser, President & CEO of Soliton, has been named as an Aesthetic Industry Association advisory board member.

Pear Therapeutics, Inc. today announced that Corey McCann, M.D., Ph.D., President and CEO, will participate in an analyst-led fireside chat and a Prescription Digital Therapeutics panel discussion at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 17. The fireside chat will be at 11:30 a.m. ET and the panel discussion, “Prescription Digital

OncoNano Medicine, Inc. today announced that a research paper titled “Prolonged activation of innate immune pathways by a polyvalent STING agonist” published in Nature Biomedical Engineering shows that a pH-sensitive nanoparticle-based drug developed by Dr. Jinming Gao and team at the University of Texas Southwestern Medical Center (UTSW

i2O Therapeutics , developers of a platform for oral delivery of traditionally injectable biological drugs, announced today a research collaboration with Sanofi to investigate the oral delivery of Sanofi’s Nanobody ® -based medicines, which are currently administered through intravenous or subcutaneous injections. Nanobodies - propr

Provides Milestones for Attaining NICE Guidance, Including Addition of UroShield to the NHS Supply Chain; Process Completion and Recommendation Expected in Q1 2022

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced it has completed enrollment of the first cohort of patients into its Phase 1b clinical study of RGLS432

Elekta announced today that the United States Department of Veterans Affairs (VA) National Radiation Oncology Program is poised to pair its major radiotherapy quality program with Elekta’s (EKTA-B.ST)